Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KURA 
Kura Oncology Inc (KURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: KURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $25.73
1 Year Target Price $25.73
| 10 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 11.1% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 503.00M USD | Price to earnings Ratio - | 1Y Target Price 25.73 |
Price to earnings Ratio - | 1Y Target Price 25.73 | ||
Volume (30-day avg) 15 | Beta 0.4 | 52 Weeks Range 5.41 - 23.48 | Updated Date 07/9/2025 |
52 Weeks Range 5.41 - 23.48 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -267.52% | Operating Margin (TTM) -458.61% |
Management Effectiveness
Return on Assets (TTM) -19.6% | Return on Equity (TTM) -41.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -135838069 | Price to Sales(TTM) 7.4 |
Enterprise Value -135838069 | Price to Sales(TTM) 7.4 | ||
Enterprise Value to Revenue 3 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 86574704 | Shares Floating 64118079 |
Shares Outstanding 86574704 | Shares Floating 64118079 | ||
Percent Insiders 1.09 | Percent Institutions 93.89 |
Upturn AI SWOT
Kura Oncology Inc
Company Overview
History and Background
Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for the treatment of cancer. Founded in 2014, Kura Oncology aims to target signaling pathways involved in cancer development.
Core Business Areas
- Drug Development: Focuses on the discovery and development of small molecule therapeutics for treating cancer by targeting specific signaling pathways and oncogenes.
Leadership and Structure
Kura Oncology is led by a management team with experience in drug development and commercialization. The organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Tipifarnib: A potent and selective inhibitor of farnesyltransferase, currently under development for the treatment of HRAS mutant solid tumors and Peripheral T-cell lymphoma. Competition includes generic cancer treatments and novel targeted therapies from companies like Verastem Oncology and others pursuing RAS pathway inhibition. There is no market share data available.
- Ziftomenib: An oral menin inhibitor being developed for the treatment of NPM1-mutant AML (acute myeloid leukemia) and KMT2A-rearranged AML. The competitors in this space include Revumenib by Syndax Pharmaceuticals. Revenue is still pending approvals; no market share is available.
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet needs and strong competition. It is driven by technological advancements, increasing prevalence of cancer, and the development of targeted therapies.
Positioning
Kura Oncology positions itself as a precision medicine company focused on developing targeted therapies for specific cancer subtypes with unmet needs. Their competitive advantage lies in their focus on well-defined oncogenic drivers.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is substantial, reaching tens of billions of dollars annually. Kura Oncology is positioned to capture a share of this market by focusing on specific patient populations.
Upturn SWOT Analysis
Strengths
- Proprietary pipeline of targeted therapies
- Strong focus on precision medicine
- Experienced management team
- Potential for first-in-class therapies
Weaknesses
- Limited commercial infrastructure
- Reliance on clinical trial success
- High cash burn rate
- Vulnerability to competition
Opportunities
- Expanding pipeline through internal discovery or acquisition
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals for lead compounds
- Targeting additional cancer subtypes with existing compounds
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- SYND
- VRSE
- MRTX
Competitive Landscape
Kura Oncology is focused on precise cancer treatments. As of today Kura Oncology does not hold any market share due to its drugs still in trials.
Growth Trajectory and Initiatives
Historical Growth: Kura Oncology's historical growth is characterized by the advancement of its drug candidates through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approvals. Analyst estimates suggest significant revenue potential if their therapies are approved.
Recent Initiatives: Recent initiatives include advancing the clinical development of Tipifarnib and Ziftomenib, presenting data at scientific conferences, and securing additional funding.
Summary
Kura Oncology is a clinical-stage biopharmaceutical company specializing in precision medicines for cancer, focusing on targeted therapies. The company shows promise because of its two potential drugs. The company's future hinges on positive clinical trial results, regulatory approvals, and successful commercialization, making it vulnerable to clinical trial failures and competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kura Oncology Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data for companies in the pre-revenue stage is generally unavailable or speculative.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kura Oncology Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-09-22 | Chairman, CEO & President Dr. Troy Edward Wilson J.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 192 | Website https://kuraoncology.com |
Full time employees 192 | Website https://kuraoncology.com | ||
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.